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We analysed the effects of tobacco and alcohol in the aetiology of Hodgkin’s lymphoma (HL), based on 340 cases and 2465 controls
enrolled in Spain, France, Italy, Germany, Ireland and Czech Republic, between 1998 and 2004. Current smokers showed a
significantly increased odds ratio (OR) of HL of 1.39 (95% confidence interval (CI)¼1.04–1.87). Analyses were also conducted
separately for subjects younger than 35 years (179 cases) and for older subjects (161 cases). For subjects below age 35, no
association was observed between tobacco and HL, whereas for older subjects, ever-smokers experienced a doubled risk of HL as
compared to never smokers and the OR of HL for current smoking was 2.35 (95% CI¼1.52–3.61), with suggestion of a dose–
response relationship. A protective effect of alcohol was observed in both age groups. The OR for ever-regular drinking was 0.58
(95% CI¼0.38–0.89) for younger subjects and 0.50 (95% CI¼0.34–0.74) for older subjects. There was no evidence of interaction
between tobacco and alcohol. Our results are consistent with previous studies, suggesting a protective effect of alcohol on HL. An
effect of tobacco was suggested for HL occurring in middle and late age, although this finding might have occurred by chance.
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Hodgkin’s lymphoma (HL) accounts for approximately 30% of all
lymphomas (Jaffe et al, 2001). In developed countries, its incidence
peaks around age 25–30 and then again after age 60 (Cartwright
and Watkins, 2004). To date, the two main known risk factors of
HL are infection with Epstein–Barr virus (EBV) with late age of
infection being potentially important (International Agency for
Research on Cancer (IARC), 1998) and infection with human
immunodeficiency virus (IARC, 1996).
Sixteen epidemiological studies have investigated the effect of
tobacco smoking on HL (Hammond and Horn, 1958; Newell et al,
1973; Paffenbarger Jr et al, 1977; Williams and Horm, 1977;
Abramson et al, 1978; Matthews et al, 1984; Bernard et al, 1987;
McLaughlin et al, 1995; Siemiatycki et al, 1995; Adami et al, 1998;
Miligi et al, 1999; Stagnaro et al, 2001; Briggs et al, 2002; Gallus
et al, 2004; Glaser et al, 2004; Nieters et al, 2005). Out of the 11
reporting an increased risk (Hammond and Horn, 1958; Paffen-
barger Jr et al, 1977; Williams and Horm, 1977; Matthews et al,
1984; McLaughlin et al, 1995; Siemiatycki et al, 1995; Adami et al,
1998; Stagnaro et al, 2001; Briggs et al, 2002; Glaser et al, 2004;
Nieters et al, 2005), three presented significant results (McLaughlin
et al, 1995; Briggs et al, 2002; Nieters et al, 2005), among which one
is part of our research (Nieters et al, 2005). These studies were
characterised by small sample size, 10 of the 15 studies being based
on less than 200 case–control pairs. As a consequence, HL is not
considered as a smoking-related cancer (Jaffe et al, 2001; IARC,
2002). The literature concerning the potential link with alcohol
drinking is based on four case–control studies (Williams and
Horm, 1977; Bernard et al, 1987; Tavani et al, 1997; Nieters et al,
2005), all reporting an apparent protective effect of alcohol. To
clarify further the potential association between tobacco, alcohol
and HL, we have investigated these associations in a European
multicentre case–control study (Epilymph) in which the serolo-
gical EBV status was tested in a subsample of subjects.
PATIENTS AND METHODS
Subjects
Our investigation was conducted in six European countries: Czech
Republic, France, Germany, Ireland, Italy and Spain. Recruitment
of histologically or cytologically confirmed incident cases of
lymphoma, among which 340 were HL, began in 1998 and ended in
2004. Cases were classified according to the World Health
Organization classification (Jaffe et al, 2001), with a central review
of 20% of the slides from each centre in order to confirm the
reliability of diagnoses reported on confirmation of HL diagnoses.
During the same period, 2465 controls were recruited. In Italy
and Germany, controls were drawn from a random sample of the
population registers of the recruitment areas. These population-
based controls were matched to cases on sex, age (5-year intervals)
and residence area. In other countries, controls were hospitalised
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ysubjects suffering from infectious and parasitic (17.6%), mental
and nervous (14.6%), circulatory (8.7%), digestive (7.1%), endo-
crine and metabolic (4.1%), respiratory (3.9%) and several other
conditions (33.2%) excluding cancer. The remaining 10.8% of
diagnoses were unspecified. These controls were matched to cases
on age (5-year intervals), sex and region.
The matching was group-based in France, Ireland, Italy and
Spain, whereas controls were individually matched to cases in
Germany and Czech Republic. The participation rates for
hospitalised and population-based controls were, respectively,
81.2 and 51.5%, whereas among cases it was 87.7%. All cases and
controls were at least 17 years of age. The study was approved by
the relevant ethical committees.
Data collection
A standard questionnaire was translated in the language of each
country and administered to all patients by locally trained
interviewers. Questions covered sociodemographic variables,
occupational, reproductive, family and medical history, ultraviolet
radiation exposures as well as lifestyle factors, including alcohol
drinking and tobacco smoking. In Germany, a slightly different
questionnaire on alcohol drinking was used (Nieters et al, 2005).
In addition, for 1033 controls and 196 cases of HL (coming from
four countries: Spain, France, Germany and Italy), two observers
independently and blind to the disease status tested the EBV status
in serum using an enzyme-linked immunosorbent assay.
Extensive information about tobacco smoking was collected for
all patients, including smoking status, type of tobacco (black or
blond), age at start, duration (years) and number of cigarettes
smoked per day for ever-smokers (ex- and current smokers
combined). An ever-smoker was defined as someone smoking at
least one cigarette per day for 6 months and a current smoker was
defined as a participant who reported smoking 2 years before the
date of interview. The number of cigarettes smoked per day was
based on the average consumption. Quantitative variables were
categorised according to tertiles of the distribution of smokers
among young and old controls separately.
Description of alcohol consumption including type of beverage
drunk (beer, wine or spirits), volume consumed per month, age at
start and duration (years) of drinking was collected for regular
drinkers defined as people declaring a daily consumption lasting
over 6 months. In Germany, a regular drinker was defined as a
man consuming more than 2g of alcohol per day. The limit was
0.5gday
 1 for women. Information related to beer, wine and
spirits was collected separately and then summed up in order to
estimate consumption for all alcohol intake combined. Lifetime
consumption (kilograms) was calculated by summing the product
obtained for each period of consumption. (Lifetime alcohol
consumption (kilograms)¼
P
i12diciwiþ
P
j12djcjwjþ
P
k12dkckwk,
where d is the duration (years), c the amount (lmonth
 1),
wi¼0.004kgl
 1, wj¼0.01kgl
 1, wk¼0.032kgl
 1, i¼beer,
j¼wine and k¼spirit) (IARC, 1988). Monthly amount of
alcohol was calculated in the same way divided by the duration
of drinking (in months). Quantitative variables were categorised
according to tertiles of the distribution of drinkers among young
and old controls separately. In Germany, because of the use of a
slightly different questionnaire, the following alcohol drinking
variables were not available: age at start, duration and lifetime
consumption.
Statistical analysis
To allow for possible aetiological differences between HL in young
vs older people (Jarrett, 2002), all analyses were stratified into two
categories (subjects younger than 35 years and subjects 35 years or
older). Odds ratios (ORs) of HL and their corresponding 95%
confidence intervals (CIs) were computed for alcohol drinking and
tobacco smoking by using logistic regression models. Odds ratio
for smoking-related variables were adjusted for sex, age (5-year
intervals), educational level (in three categories) and consumption
of alcohol per month (in three categories). Similarly, OR for
alcohol drinking were adjusted for sex, age (5-year intervals),
educational level (in three categories) and smoking status (in three
categories). Never smokers were the reference category for the
analyses on tobacco smoking and never-regular drinkers were the
reference category for each of the analyses on alcohol drinking.
Linear trends were calculated by including categorical exposure
variables in the multivariate regression models, whose significance
was tested by the Wald test. In order to test the heterogeneity of
risk by sex and by centre, an interaction term was added to the
regression model and its significance was tested by the likelihood
ratio statistic. Breslow and Day tests were performed to test
homogeneity between EBV-positive HL vs EBV-negative HL as well
as between the two main histological types of HL, nodular sclerosis
(HLNS) and mixed cellularity (HLMC). Additionally, to test the
interaction between smoking and alcohol, a binary interaction
term was included. Analyses were conducted using Statistical
Analysis System software version (SAS Institute Inc, 2004).
RESULTS
The 340 identified HL were composed of 24 nodular lymphocyte
predominant HL and 316 classical HL, which were made up of 193
HLNS, 69 HLMC, nine lymphocyte-rich HL, four lymphocyte-
depleted HL and 41 classical HL not otherwise specified (nos.). As
reported in Table 1, in both age groups, over 90% of the cases were
diagnosed as classical HL. Cases of HLNS, which is the main
histological subtype, represented two-thirds of the cases less than
35 years old and 45% of the older cases. With respect to
sociodemographical variables, the younger cases were similar to
the controls, whereas older subjects were more educated than
controls.
In Table 2, detailed results of the analysis of the effects of
smoking are presented regardless of age and by age for HL overall
and for HLNS. Overall, tobacco smoking increased risks of HL with
an OR of 1.33 (95% CI¼1.02–1.74) for ever-smokers and an OR of
1.39 (95% CI¼1.04–1.87) for current smokers. Among younger
subjects, no association was observed between smoking and HL.
Among older subjects, increased risks of HL overall were observed
with an almost doubled OR for ever-smokers and an OR of 2.35
(95% CI¼1.52–3.61) for current smokers. A trend in OR was
observed with cumulative smoking expressed as pack-years. On
the other hand, no dose–response relationship was observed with
cigarettes smoked per day, age at start or duration of smoking.
There was no evidence of heterogeneity of the effect of tobacco on
the development of HLMC vs HLNS (P¼0.87). For both
histological subtypes, current smokers displayed a more than
two-fold increased risk of HL but no dose–response relationship
was observed.
Table 3 reports the results of HL risk for alcohol drinking.
Overall, a protective effect was observed with an OR of 0.61 (95%
CI¼0.43–0.87) for ever-regular drinkers, reaching 0.56 (95%
CI¼0.42–0.74) when cases and controls from Germany were
included (data not shown). Among younger subjects, a protective
effect of ever-regular drinking on HL was observed. Inclusion of
cases and controls from Germany resulted in an OR of 0.58 (95%
CI¼0.38–0.89) for ever drinking. No trend was observed for
increasing level, except for duration of drinking. The protective
effect was observed for HLNS but not for HLMC (data not shown).
Results on alcohol drinking among older subjects were similar to
those observed among young subjects; in particular, the inclusion
of cases and controls from Germany resulted in an OR of 0.50 (95%
CI¼0.34–0.74) for ever drinking. A dose–response relationship
was suggested with lifetime consumption of alcohol.
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ever drinking status among either young (P¼0.72) or older
subjects (P¼0.40). Among the older subjects, the increased risk of
HL owing to smoking was equal to 2.66 (95% CI¼1.06–6.65) for
regular drinkers and 2.11 (95% CI¼0.98–4.57) for nonregular
drinkers, and no evidence of heterogeneity of the effect of tobacco
was observed on the development of EBV-negative HL vs EBV-
positive HL (P¼0.53). There was no evidence of heterogeneity
looking at the effect of alcohol on development of EBV-negative
HL vs EBV-positive HL for either young (P¼0.54) or older
subjects (P¼0.25).
DISCUSSION
This European study involving 340 cases of HL and 2465 controls
suggested that among subjects older than 35 years but not among
younger subjects, tobacco smoking increased the risk of HL. On
the other hand, alcohol drinking was suggested to decrease the risk
of HL in both young and old subjects. These results have little
support from the epidemiological literature, although this is
characterised by a limited number of studies investigating the
effect of alcohol and stratifying the effect of tobacco by age. No
interaction between smoking status and alcohol consumption on
the risk of HL was present, which to our knowledge has never been
investigated previously.
Our study has several methodological strengths. The question-
naire was administered in the same manner to all subjects, cases
and controls. All HL patients are incident cases and their diagnoses
have been histologically or cytologically confirmed. Diagnoses of
97 cases were reviewed centrally: of them, 83 (85.6%) cases were
validated, 13 (13.4%) were reclassified between HL subtypes and
one was inconclusive. The distribution of the different histological
subtypes of HL was comparable to those reported worldwide (Jaffe
et al, 2001). Hospital-based controls were recruited in the same
hospitals or hospitals from the same recruitment areas as the cases;
with regards population-based controls, in addition to matching
for age and sex, they were frequency matched for residential area
insuring that controls were drawn from the same source
population as the case series. The two centres recruiting
population-based controls reported similar results as the four
centres recruiting hospital-based controls.
Nonetheless, consideration must be given to potential limita-
tions of our investigation. Cases and controls were characterised
by refusal rates of 12.3 and 31%, respectively. If nonparticipants
drink or smoke differently than included subjects, this may lead to
over- or underestimating the true ORs. As participants were asked
to report habits for many years before interview, there may have
also been some exposure misclassification. If this misclassification
was undifferential, this would dilute observation of associations
and dose–response relationships, whereas if this misclassification
was differential, it would exaggerate or decrease observation of
associations. Furthermore, alcohol and even more tobacco are
well-known risk factors of cancer. This may result in higher recall
among cases than controls, potentially leading to overestimating
the effect of risk factors and to underestimating the protective
effects. In addition, the EBV status at our disposal was a serological
one, which cannot necessarily be interpreted as part of the
malignant process.
The evidence of a positive association between tobacco smoking
and HL risk among subjects over 35 years old was strengthened by
our observation of a dose–risk relationship for number of pack-
years, although there was no significant heterogeneity in risk by
age of smoking duration using the same categories of smoking
duration (P¼0.11). The difference of risk of HL observed by age
might not be a consequence of longer smoking duration among
older subjects. For most tobacco-related cancers, a carcinogenic
effect of tobacco is also apparent among young subjects (IARC,
2002). Our data add further evidence that the young-onset HL and
the late-onset HL are two different diseases with likely different
aetiological pathways.
Table 1 Sociodemographic characteristics of HL cases and their controls
by age groups
Controls n¼2465 Cases n¼340
n % n %
Subjects o35 years old
Histology
HLNS 121 67.6
HLMC 29 16.2
Other classical HL 19 10.6
Unclassical HL 10 5.6
Sex
Male 162 51.9 90 50.3
Female 150 48.1 89 49.7
Age (years)
o25 106 34.0 66 36.9
X25 and o30 99 31.7 71 39.7
X30 and o35 107 34.3 42 23.5
Educational level
Missing data 1 0
Low 55 17.7 29 16.2
Medium 192 61.7 117 65.4
High 64 20.6 33 18.4
Lifetime residence
Missing data 1 0
Never rural 178 57.2 95 53.1
Ever rural 133 42.8 84 46.9
Subjects X35 years old
Histology
HLNS 72 44.7
HLMC 40 24.8
Other classical HL 35 21.7
Unclassical HL 14 8.7
Sex
Male 1160 53.9 95 59.0
Female 993 46.1 66 41.0
Age
X35 and o40 134 6.2 43 26.7
X40 and o45 144 6.7 22 13.7
X45 and o50 172 8.0 17 10.6
X50 and o55 243 11.3 22 13.7
X55 and o60 255 11.8 15 9.3
X60 and o65 309 14.4 13 8.1
X65 and o70 342 15.9 12 7.5
X70 and o75 277 12.9 8 5.0
X75 and o80 212 9.9 8 5.0
X80 and o85 50 2.3 1 0.6
X85 and o100 15 0.7 0 0.0
Educational level
Missing data 0 1
Low 1067 49.6 65 40.6
Medium 809 37.6 65 40.6
High 277 12.9 30 18.8
Lifetime residence
Missing data 1 1
Never rural 849 39.5 63 39.4
Ever rural 1303 60.6 97 60.6
HL¼Hodgkin’s lymphoma. HLNS¼Hodgkin’s lymphoma nodular sclerosis.
HLMC¼Hodgkin’s lymphoma mixed cellularity.
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Controls n¼2465
All HL, n¼340 Nodular sclerosis HL, n¼193
nn OR
a (95% CI) n OR
a (95% CI)
Subjects overall
Never smoker 1095 135 83
Ever smoker 1361 203 1.33 (1.02–1.74) 108 1.16 (0.82–1.64)
Blond tobacco 572 95 1.20 (0.83–1.73) 61 1.20 (0.76–1.90)
Black tobacco 433 44 1.69 (1.03–2.79) 25 1.76 (0.92–3.38)
Ex-smoker 711 61 1.22 (0.85–1.76) 34 1.31 (0.81–2.11)
Current smoker 650 142 1.39 (1.04–1.87) 74 1.10 (0.75–1.61)
Subjects o35 years old
Never smoker* 134 88 63
Ever smoker 176 91 0.89 (0.60–1.32) 58 0.79 (0.50–1.24)
Blond tobacco 108 52 0.93 (0.57–1.54) 38 0.92 (0.52–1.62)
Black tobacco 24 12 1.15 (0.46–2.87) 9 1.22 (0.43–3.41)
Ex-smoker 32 19 1.05 (0.54–2.05) 16 1.31 (0.63–2.72)
Current smoker 144 72 0.86 (0.57–1.29) 42 0.68 (0.42–1.12)
Cigarettes per day
o8 55 31 0.98 (0.58–1.68) 22 0.97 (0.52–1.78)
X8 and o15 51 25 0.77 (0.44–1.36) 19 0.78 (0.41–1.48)
X15 70 31 0.84 (0.49–1.44) 13 0.51 (0.25–1.05)
P trend
b 0.83 0.83
Age at start (years)
X18 60 30 0.88 (0.52–1.51) 21 0.93 (0.50–1.73)
415 and o18 52 32 1.07 (0.62–1.84) 19 0.83 (0.44–1.58)
p15 64 27 0.72 (0.41–1.26) 16 0.57 (0.29–1.12)
P trend
b 0.63 0.32
Duration (years)
p6 63 28 0.70 (0.41–1.21) 19 0.64 (0.34–1.20)
46a n dp12 62 38 1.01 (0.60–1.68) 27 1.01 (0.56–1.82)
412 51 23 1.01 (0.53–1.95) 10 0.63 (0.26–1.50)
P trend
b 0.23 0.13
Pack-years
p2 55 29 0.87 (0.50–1.49) 24 0.98 (0.54–1.79)
42a n do7 59 34 0.97 (0.57–1.62) 21 0.81 (0.44–1.49)
X7 62 25 0.77 (0.42–1.39) 10 0.43 (0.19–0.96)
P trend
b 0.45 0.08
Subjects X35 years old
Never smoker** 961 47 20
Ever smoker 1185 112 1.96 (1.33–2.89) 50 2.17 (1.22–3.88)
Blond tobacco 464 43 1.68 (0.97–2.89) 23 2.09 (0.94–4.68)
Black tobacco 409 32 2.13 (1.13–4.01) 16 2.29 (0.89–5.90)
Ex-smoker 679 42 1.58 (0.99–2.51) 18 1.77 (0.88–3.56)
Current smoker 506 70 2.35 (1.52–3.61) 32 2.56 (1.35–4.85)
Cigarettes per day
o10 308 26 1.81 (1.07–3.06) 11 1.93 (0.87–4.24)
X10 and o20 390 39 1.95 (1.21–3.14) 16 1.84 (0.89–3.78)
X20 475 47 2.16 (1.35–3.48) 23 2.90 (1.45–5.82)
P trend
b 0.13 0.49
Age at start (years)
X20 416 35 1.99 (1.24–3.22) 15 2.23 (1.09–4.55)
416 and o20 304 30 1.94 (1.16–3.25) 11 1.81 (0.81–4.06)
p16 462 47 1.95 (1.21–3.14) 24 2.39 (1.20–4.77)
P trend
b 0.20 0.49
Duration (years)
p21 428 35 1.14 (0.70–1.87) 17 1.21 (0.59–2.49)
421 and p35 383 50 2.91 (1.82–4.67) 21 3.40 (1.66–6.99)
435 371 27 3.05 (1.74–5.35) 12 4.40 (1.88–10.33)
P trend
b 0.13 0.26
Pack-years
p11 391 26 1.14 (0.67–1.93) 12 1.18 (0.53–2.59)
411 and o30 386 47 2.43 (1.53–3.86) 19 2.33 (1.15–4.73)
X30 405 39 2.95 (1.77–4.91) 19 4.78 (2.23–10.26)
P trend
b 0.04 0.08
HL¼Hodgkin’s lymphoma; OR¼odds ratio. *Reference category for all smoking variables among subjects o35 years old. **Reference category for all smoking variables among
subjects X35 years old.
aAdjusted for age, sex, educational level, alcohol monthly consumption and centre.
bP trend using ever-smokers only (excludes never smokers) and
adjusted for the other smoking variables in the table.
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a
Controls n¼1755
All HL, n¼224 Nodular sclerosis HL, n¼137
nn OR
b 95% CI n OR
b 95% CI
Subjects overall
Never regular drinker 876 141 88
Ever regular drinker 866 81 0.61 (0.43–0.87) 47 0.58 (0.37–0.92)
Beer drinker 507 57 0.63 (0.41–0.94) 34 0.60 (0.35–1.02)
Wine drinker 645 43 0.57 (0.37–0.88) 23 0.60 (0.34–1.06)
Spirits drinker 284 42 0.78 (0.50–1.22) 25 0.68 (0.38–1.20)
Subjects o35 years old
Never regular drinker* 119 83 61
Ever regular drinker 96 40 0.63 (0.37–1.09) 28 0.62 (0.33–1.16)
Beer drinker 69 33 0.76 (0.41–1.39) 23 0.78 (0.38–1.59)
Wine drinker 41 12 0.49 (0.22–1.10) 7 0.44 (0.16–1.19)
Spirits drinker 46 24 0.78 (0.41–1.51) 17 0.70 (0.33–1.50)
Monthly consumption (g)
p66 6 3 0.79 (0.18–3.51) 2 1.13 (0.18–7.17)
466 and p341 13 4 0.56 (0.16–2.01) 2 0.46 (0.09–2.50)
4341 24 9 0.72 (0.27–1.89) 7 0.91 (0.29–2.80)
P trend
c 0.17 0.44
Age at start (years)
X18 38 19 0.75 (0.38–1.47) 11 0.57 (0.25–1.30)
X16 and o18 35 13 0.50 (0.23–1.12) 10 0.54 (0.22–1.33)
o16 22 6 0.46 (0.17–1.26) 6 0.76 (0.26–2.22)
P trend
c 0.52 0.64
Duration (years)
p7 35 15 0.57 (0.27–1.19) 13 0.62 (0.28–1.39)
47 and p13 35 12 0.47 (0.21–1.05) 6 0.28 (0.10–0.81)
413 25 11 1.01 (0.40–2.56) 8 1.57 (0.52–4.75)
P trend
c 0.03 0.18
Lifetime consumption (kg)
o16 27 8 0.44 (0.18–1.06) 4 0.29 (0.09–0.92)
X16 and o61 31 14 0.66 (0.31–1.41) 10 0.69 (0.29–1.65)
X61 36 16 0.76 (0.35–1.64) 13 0.96 (0.40–2.33)
P trend
c 0.07 0.16
Subjects X35 years old
Never regular drinker** 757 58 27
Ever regular drinker 770 41 0.58 (0.35–0.94) 19 0.52 (0.26–1.04)
Beer drinker 438 24 0.51 (0.28–0.92) 11 0.42 (0.18–0.98)
Wine drinker 604 31 0.58 (0.34–1.01) 16 0.67 (0.32–1.42)
Spirits drinker 238 18 0.71 (0.38–1.36) 8 0.57 (0.23–1.43)
Monthly consumption (g)
p215 121 5 0.52 (0.20–1.38) 3 0.58 (0.16–2.08)
4215 and p734 249 13 0.63 (0.32–1.24) 7 0.64 (0.25–1.60)
4734 274 19 0.66 (0.35–1.26) 7 0.47 (0.18–1.25)
P trend
c 0.09 0.40
Age at start (years)
422 216 12 0.72 (0.36–1.42) 7 0.82 (0.33–2.05)
418 and p22 203 7 0.44 (0.19–1.04) 3 0.41 (0.12–1.48)
p18 320 22 0.63 (0.34–1.15) 9 0.45 (0.18–1.10)
P trend
c 0.88 0.31
Duration (years)
p29 238 20 0.53 (0.29–0.97) 10 0.47 (0.20–1.11)
429 and p44 266 15 0.73 (0.37–1.44) 5 0.53 (0.18–1.57)
444 253 6 0.51 (0.19–1.38) 4 0.76 (0.21–2.77)
P trend
c 0.60 0.40
Lifetime consumption (kg)
o143 221 16 0.72 (0.39–1.33) 9 0.76 (0.33–1.76)
X143 and o425 259 14 0.55 (0.28–1.09) 5 0.38 (0.13–1.09)
X425 259 11 0.50 (0.23–1.07) 5 0.44 (0.15–1.33)
P trend
c 0.07 0.23
CI¼confidence interval; HL¼Hodgkin’s lymphoma; OR¼odds ratio. *Reference category for all alcohol variables among subjects o35 years old. **Reference category for all
alcohol variables among subjects X35 years old.
aExcluding data from Germany.
bAdjusted for age, sex, educational level, smoking status and centre.
cP trend using ever-regular
drinkers only (excludes never-regular drinkers) and adjusted for the other alcohol variables in the table.
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reported or suggested by several studies (Hammond and Horn,
1958; Paffenbarger Jr et al, 1977; Williams and Horm, 1977;
Matthews et al, 1984; McLaughlin et al, 1995; Siemiatycki et al,
1995; Adami et al, 1998; Stagnaro et al, 2001; Briggs et al, 2002;
Glaser et al, 2004), HL has not been regarded as a smoking-related
cancer (Jaffe et al, 2001; IARC, 2002). Out of the five previous
investigations stratifying the analyses by age or restricting
inclusion to subjects over 35 years old, two American studies
reported significant increased risks of HL owing to smoking
(McLaughlin et al, 1995; Briggs et al, 2002). One was a cohort study
composed of 248046 US Veterans with 3000000 person-years of
observation accumulated, which reported a significant relative risk
of 1.5 for current smokers (McLaughlin et al, 1995). The other was
a male population-based case–control study, in which current
smokers over 42 years old had a significant doubled risk of HL
(Briggs et al, 2002). However, no heterogeneity in risk was
observed by comparing subjects younger vs older than 42 years
(Briggs et al, 2002). The three other studies whose results were
based on older subjects were a Canadian case–control study
(Siemiatycki et al, 1995) and two cohort studies conducted in
Sweden (Adami et al, 1998) and the USA (Hammond and Horn,
1958); these reported insignificant increased risk of HL owing to
smoking. Four studies investigated the dose–response relation-
ship, but none stratified analyses by age (Stagnaro et al, 2001;
Briggs et al, 2002; Gallus et al, 2004; Glaser et al, 2004).
The inverse association between alcohol and HL is consistent
with results from three case–control studies carried out in Italy
(Tavani et al, 1997), United Kingdom (Bernard et al, 1987) and
USA (Williams and Horm, 1977), which reported reduced OR of
HL ranging from 0.5 to 0.9. Our results are weakened by lack of
observation of a dose—response, except with lifetime consump-
tion for which a dose–response relationship was suggested among
both younger and older subjects. None of the previous studies
investigated in detail the dose–risk relationship with alcohol
drinking.
It is possible that alcohol is proapoptotic and acts like aspirin
(Chang et al, 2004) by inhibiting the transcription nuclear factor-
kB (Guizzetti et al, 2003; Saeed et al, 2004). Nuclear factor-kB
initiates transcription of antiapoptotic genes such as bcl-2 and has
been found to be constitutively activated in the Hodgkin and
Reed–Sternberg (HRS) cells (Kuppers and Hansmann, 2005)
blocking in this manner the apoptotic pathway. In contrast,
inhibition of active NF-kB decreases proliferation and causes
spontaneous apoptosis of HRS cells (Bargou et al, 1997; Hinz et al,
2001; Izban et al, 2001). Within the subsample with documented
EBV, subjects with negative EBV status did not drink more than
those positive for EBV status (data not shown). On the other hand,
the inverse association between alcohol drinking and HL might
also be owing to unmeasured confounding factors.
In conclusion, on the basis of the findings of this study, one of
the largest on this subject in Europe, smoking increases the risk of
HL among subjects older than 35 years but not among younger
subjects. The results also suggest that regular alcohol drinking is
associated with a decreased risk of HL in both age groups.
However, our findings must be treated with caution and further
evidence is needed, especially on alcohol drinking.
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